NEWTOWN, Pa.--(BUSINESS WIRE)--Feb. 27, 2006--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced today that a Marketing Authorization Application (MAA) for Oracea(TM), has been filed with the United Kingdom's Medicines & Healthcare Products Regulatory Agency (MHRA). The UK will act as reference member state in this decentralized procedure. The MAA for Oracea was submitted to the MHRA on February 24, 2006. A New Drug Application for Oracea was filed with the U.S. Food and Drug Administration in August 2005 and has been given a PDUFA date of May 31, 2006. If approved, Oracea will be the first orally administered, systemically delivered drug developed to treat rosacea.
